XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.21

-1.9%

11:53 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (4892)	11/26/1997 9:28:00 AM
From: Webhead	Read Replies (3) of 17367

Idec just got FDA approval for their anti-CD20 monoclonal! Just a reminder that XOMA gets royalties on this. From the PR it appears that royalties will actually come from Genentech (GNE and IDPH are cross licensed if I remember correctly). In the Idec thread, it was reported that some analyst's most recent market projection for this antibody in its uncoupled and radioactive forms is ~$500 million a year. So given even modest royalties this could mean some $10 million or so a year to XOMA. Ed ------ www1.newsalert.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next